{"version":"1.0","type":"link","title":"Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive-stage small-cell lung cancer: Results of two prospective phase II studies.","author_name":"Yu S 외","author_url":"https://prs-insight.online/author/Yu%20S","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/94974","thumbnail_width":1200,"thumbnail_height":630}